Advertisement

HPLC Analysis of the Major Urinary Metabolite of Flurazepam

  • J. A. F. de Silva
  • M. A. Brooks
  • M. R. Hackman
  • R. E. Weinfeld
Part of the Methodological Surveys in Biochemistry and Analysis book series (MSBA, volume 12)

Abstract

Pharmacokinetic parameters of a drug are commonly evaluated by the determination of unchanged drug in blood or plasma. An acceptable alternative [1], especially if a non-invasive method is desired, is to use urinary excretion data for either the unchanged drug or a major metabolite. If the latter represents a significant percentage of the administered dose, its quantitation places fewer constraints on the sensitivity required of the analytical procedure, and on the sample preparation and ‘clean-up’ required prior to analysis. HPLC, either normal-phase (NP) or reverse-phase (RP), is ideally suited to this type of determination [2]. RP conditions have now been developed.

Keywords

Unchanged Drug Control Urine Differential Pulse Polarography Urinary Excretion Data Major Urinary Metabolite 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Federal Register (1977) 42 (5) , 1624–1653Google Scholar
  2. 2.
    de Silva, J.A.F. (1981) in Trace-Organic Sample Handling (Vol. 11, this series; Reid, E., ed.) , Horwood, Chichester, pp. 192–204.Google Scholar
  3. 3.
    Schwartz, M.A. & Postma, E. (1970)J. Pharm. Sci. 59, 1800–1806.CrossRefGoogle Scholar
  4. 4.
    de Silva, J.A.F. & Strojny, N. (1971)J. Pharm. Sci. 60, 1303–1314.CrossRefGoogle Scholar
  5. 5.
    de Silva, J.A.F., Puglisi, C.V., Brooks, M.A. & Hackman, M.R. (1974)J. Chromatog. 99, 461–483.CrossRefGoogle Scholar
  6. 6.
    Peat, M.A. & Kopjak, L. (1979)J. Forens Sci. 24, 46–54.Google Scholar
  7. 7.
    de Silva, J.A.F., Bekersky, I. & Puglisi, C.V. (1974) J. Pharm.Sci. 63, 1837–1841.Google Scholar
  8. 8.
    Glover, W., Earley, J., Delaney, M. Dixon, R. (1980)J. Pharm. Sci. 69, 601–602.CrossRefGoogle Scholar
  9. 9.
    Clatworthy, A.J., Jones, L.V. & Whitehouse, M.J. (1977)Biomed Mass Spectrometry4, 248–254CrossRefGoogle Scholar
  10. 10.
    Miwa, B.J., Garland, W.A. & Blumenthal, P. (1981)Anal. Chem. 54, 793–797CrossRefGoogle Scholar
  11. 11.
    Weinfeld, R.E. & Miller, K.F. (1981)J. Chromatog. 223, 123–130.CrossRefGoogle Scholar
  12. 12.
    Brooks, M.A. (1980) in Electroanalysis in Hygiene, Environmental, Clinical and Pharmaceutical Chemistry (Franklin-Smyth, W., ed.) , Elsevier, Amsterdam, pp. 287–298.Google Scholar
  13. 13.
    Kackman, M.R. & Brooks, M.A. (1981)J. Chromatog. 222, 179–190.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1983

Authors and Affiliations

  • J. A. F. de Silva
    • 1
  • M. A. Brooks
    • 1
  • M. R. Hackman
    • 1
  • R. E. Weinfeld
    • 1
  1. 1.Department of Pharmacokinetics and BiopharmaceuticsHoffmann-La Roche Inc.NutleyUSA

Personalised recommendations